INmune Bio (NASDAQ:INMB) Given New $14.00 Price Target at BTIG Research

INmune Bio (NASDAQ:INMBGet Rating) had its price target reduced by analysts at BTIG Research from $31.00 to $14.00 in a research note issued on Tuesday, The Fly reports. BTIG Research’s price objective would indicate a potential upside of 183.98% from the company’s previous close.

INMB has been the subject of a number of other reports. Maxim Group assumed coverage on shares of INmune Bio in a research note on Friday, May 6th. They issued a “buy” rating and a $22.00 price objective for the company. B. Riley lowered shares of INmune Bio from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $14.00 to $7.00 in a research note on Tuesday. Finally, Zacks Investment Research raised shares of INmune Bio from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Friday, May 13th.

Shares of INMB opened at $4.93 on Tuesday. The firm has a market capitalization of $88.47 million, a P/E ratio of -3.77 and a beta of 2.44. INmune Bio has a 12-month low of $6.18 and a 12-month high of $30.37. The company has a current ratio of 23.89, a quick ratio of 23.89 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average price of $7.80 and a 200-day moving average price of $9.52.

INmune Bio (NASDAQ:INMBGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. During the same quarter in the previous year, the business earned ($0.32) earnings per share. Analysts predict that INmune Bio will post -2.02 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in the business. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of INmune Bio during the third quarter valued at about $31,000. Royal Bank of Canada boosted its position in INmune Bio by 90.2% in the 3rd quarter. Royal Bank of Canada now owns 126,411 shares of the company’s stock worth $2,455,000 after purchasing an additional 59,953 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in INmune Bio by 14.7% in the 4th quarter. Janney Montgomery Scott LLC now owns 113,914 shares of the company’s stock worth $1,162,000 after purchasing an additional 14,591 shares in the last quarter. Fermata Advisors LLC boosted its position in INmune Bio by 39.9% in the 4th quarter. Fermata Advisors LLC now owns 17,955 shares of the company’s stock worth $183,000 after purchasing an additional 5,125 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in INmune Bio in the 4th quarter worth approximately $175,000. Institutional investors and hedge funds own 13.91% of the company’s stock.

About INmune Bio (Get Rating)

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

Featured Articles

The Fly logo

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.